🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)

RecruitingNAAges 18 Years - anyAllInstitut Claudius Regaud
NCT06797037 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral treatment. The study will be conducted on a population of 33 patients. In current practice, patients with certain solid cancers or haematological malignancies may be prescribed oral chemotherapy on a retroceded basis. In these cases, the oncologist (coordinating investigator) sees the patient for a consultation every 3 cycles to prescribe/renew the treatment for approximately 3 months. Every month, the patient returns to the centre to have the treatment dispensed by the hospital pharmacy. No medical consultation is associated with this visit. In this study, it is proposed to decentralise the delivery of treatment to these patients by introducing two visits to th

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patient over 18. 2. A patient with solid cancer or haematological malignancy receiving oral retroceded therapy as part of standard management. 3. Patient with a performance index (ECOG): 0-2. 4. Patient contactable by telephone for follow-up by the Advanced Practice Nurse. 5. Patient willing to make two home visits within 6 months of inclusion. Exclusion Criteria: 1. Pregnant or breast-feeding patient. 2. Any psychological, family, geographical or social condition which, in the judgement of the oncologist, could potentially prevent the collection of informed consent or hinder compliance with the study protocol. 3. Patients deprived of their liberty by administrative or legal decision, or patients under guardianship.
💊

What it tests

  • Decentralised Pathway Coordinated by the Advanced Practice Nurse
📍

Where

1 site
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy